{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:34:47Z","timestamp":1764599687566,"version":"3.46.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["22202MFDS176"],"award-info":[{"award-number":["22202MFDS176"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.virol.2024.110243","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T02:52:06Z","timestamp":1726455126000},"page":"110243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Chimeric adenovirus-based herpes zoster vaccine with the tPA signal peptide elicits a robust T-cell immune response"],"prefix":"10.1016","volume":"600","author":[{"given":"Sun Ok","family":"Jang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Ju","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Seok","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myeongcheol","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Ok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Pyo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2024.110243_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-med-043021-015237","article-title":"SARS-CoV-2 vaccination-induced thrombotic thrombocytopenia: a rare but serious immunologic complication","volume":"74","author":"Abrams","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.virol.2024.110243_bib2","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2017.05.032","article-title":"ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice","volume":"35","author":"Alharbi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2024.110243_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048322","article-title":"AT cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+ M1 in adults aged over 50 years","volume":"7","author":"Antrobus","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.virol.2024.110243_bib4","article-title":"Development of adenovirus-based COVID-19 vaccine candidate in Indonesia","volume":"222\u2013232","author":"Artarini","year":"2024","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.virol.2024.110243_bib5","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1016\/j.vaccine.2019.09.031","article-title":"VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: the SHEZ study","volume":"37","author":"Asada","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2024.110243_bib6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1128\/JVI.00913-08","article-title":"Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and differentially affects cell-cell spread and viral entry","volume":"83","author":"Berarducci","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110243_bib7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.0912373107","article-title":"Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection","volume":"107","author":"Berarducci","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.virol.2024.110243_bib8","first-page":"2773","article-title":"Varicella-zoster virus replication, pathogenesis, and management","volume":"2","author":"Cohen","year":"2006","journal-title":"Fields Virol."},{"key":"10.1016\/j.virol.2024.110243_bib9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110243_bib10","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"Dendouga","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.virol.2024.110243_bib11","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1086\/368196","article-title":"Treatment and prevention of postherpetic neuralgia","volume":"36","author":"Dworkin","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110243_bib12","doi-asserted-by":"crossref","first-page":"e1345","DOI":"10.1002\/cti2.1345","article-title":"Adenoviral vector\u2010based platforms for developing effective vaccines to combat respiratory viral infections","volume":"10","author":"Elkashif","year":"2021","journal-title":"Clin. Transl. Immunology."},{"key":"10.1016\/j.virol.2024.110243_bib13","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","article-title":"Chimpanzee adenoviral vectors as vaccines for outbreak pathogens","volume":"13","author":"Ewer","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virol.2024.110243_bib14","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1080\/21645515.2016.1154247","article-title":"Comparative preclinical evaluation of AS01 versus other adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine","volume":"12","author":"Fochesato","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virol.2024.110243_bib15","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(21)00103-X","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2\/3 clinical trial","volume":"8","author":"Frater","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.virol.2024.110243_bib16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1086\/375828","article-title":"Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination","volume":"188","author":"Frey","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110243_bib17","series-title":"Varicella-Zoster Virus","first-page":"291","article-title":"Simian varicella virus: molecular virology","author":"Gray","year":"2010"},{"key":"10.1016\/j.virol.2024.110243_bib18","series-title":"The Predominant Varicella-Zoster Virus gE and gI Glycoprotein Complex. Structure-Function Relationships of Human Pathogenic Viruses","first-page":"195","author":"Grose","year":"2002"},{"key":"10.1016\/j.virol.2024.110243_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002367","article-title":"CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection","volume":"7","author":"Haberthur","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virol.2024.110243_bib20","article-title":"Vector delivery-dependent effect of human tissue plasminogen activator signal peptide on vaccine induction of T cells","volume":"2","author":"Hanke","year":"2016","journal-title":"J. HIV Aids"},{"issue":"Suppl. 2","key":"10.1016\/j.virol.2024.110243_bib21","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1093\/infdis\/jiab387","article-title":"Herpes zoster vaccines","volume":"224","author":"Harbecke","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110243_bib22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-1702(95)01270-2","article-title":"Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells","volume":"40","author":"Haumont","year":"1996","journal-title":"Virus Res."},{"key":"10.1016\/j.virol.2024.110243_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/bit.27945","article-title":"Manufacturing a chimpanzee adenovirus\u2010vectored SARS\u2010CoV\u20102 vaccine to meet global needs","volume":"119","author":"Joe","year":"2022","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.virol.2024.110243_bib24","doi-asserted-by":"crossref","first-page":"9772","DOI":"10.1128\/JVI.00564-06","article-title":"Persistent high frequencies of varicella-zoster virus ORF4 protein-specific CD4+ T cells after primary infection","volume":"80","author":"Jones","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2024.110243_bib25","article-title":"Adenoviral vectors as vaccines for emerging avian influenza viruses","volume":"11","author":"Kerstetter","year":"2020","journal-title":"Front. Immunol."},{"year":"2022","series-title":"Lee S GeneMatrix, Inc. (Inventor). Assignee. Recombinant Chimeric Adenovirus Vector Substituted with the Knob Gene of Chimpanzee Adenovirus Serotype 6 and Use of the Same","author":"Kim","key":"10.1016\/j.virol.2024.110243_bib26"},{"key":"10.1016\/j.virol.2024.110243_bib27","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/infdis\/jiv164","article-title":"Zoster vaccination increases the breadth of CD4+ T cells responsive to varicella zoster virus","volume":"212","author":"Laing","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110243_bib28","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110243_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4167\/jbv.2021.51.3.103","article-title":"Immune responses to varicella zoster virus and effective vaccines","volume":"51","author":"Lee","year":"2021","journal-title":"J. Bacteriol. Virol."},{"key":"10.1016\/j.virol.2024.110243_bib30","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jis497","article-title":"A phase 1\/2 clinical trial evaluating safety and immunogenicity of a Varicella zoster glycoprotein e subunit vaccine candidate in young and older adults","volume":"206","author":"Leroux-Roels","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2024.110243_bib31","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1172\/JCI121484","article-title":"Th1 memory differentiates recombinant from live herpes zoster vaccines","volume":"128","author":"Levin","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.virol.2024.110243_bib32","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.virs.2022.06.002","article-title":"LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix\u2122 in VZV-primed mice","volume":"37","author":"Luan","year":"2022","journal-title":"Virol. Sin."},{"key":"10.1016\/j.virol.2024.110243_bib33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jviromet.2008.08.011","article-title":"Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice","volume":"154","author":"Luo","year":"2008","journal-title":"J. Virol Methods"},{"key":"10.1016\/j.virol.2024.110243_bib34","doi-asserted-by":"crossref","first-page":"e568","DOI":"10.1016\/S2352-3018(21)00157-0","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B\/2A trial","volume":"8","author":"Madhi","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.virol.2024.110243_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Mendon\u00e7a","year":"2021","journal-title":"npj Vaccines"},{"issue":"3","key":"10.1016\/j.virol.2024.110243_bib36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/vetsci6030064","article-title":"A multi-hemagglutinin-based enzyme-linked immunosorbent assay to serologically detect influenza A virus infection in animals","volume":"6","author":"Miki","year":"2019","journal-title":"Veterinary sciences"},{"key":"10.1016\/j.virol.2024.110243_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2011-000223","article-title":"A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults","volume":"1","author":"Minassian","year":"2011","journal-title":"BMJ Open"},{"key":"10.1016\/j.virol.2024.110243_bib38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1006\/viro.2002.1556","article-title":"The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells","volume":"304","author":"Mo","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.virol.2024.110243_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157031","article-title":"Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV","volume":"7","author":"Ogbe","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.virol.2024.110243_bib40","first-page":"25","article-title":"The structures and functions of VZV glycoproteins","volume":"438","author":"Oliver","year":"2023","journal-title":"Curr. Top. Environ. Microbiol."},{"key":"10.1016\/j.virol.2024.110243_bib41","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s40588-016-0044-4","article-title":"Varicella-zoster virus glycoproteins: entry, replication, and pathogenesis","volume":"3","author":"Oliver","year":"2016","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"10.1016\/j.virol.2024.110243_bib42","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2024.110243_bib43","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.virol.2024.110243_bib44","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1086\/592219","article-title":"Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-\u03b3 enzyme-linked immunospot assay","volume":"198","author":"Sadaoka","year":"2008","journal-title":"J. Infect. Dis."},{"year":"1989","series-title":"Molecular Cloning: a Laboratory Manual","author":"Sambrook","key":"10.1016\/j.virol.2024.110243_bib45"},{"key":"10.1016\/j.virol.2024.110243_bib46","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3389\/fimmu.2015.00553","article-title":"Effector and central memory poly-functional CD4(+) and CD8(+) T cells are Boosted upon ZOSTAVAX\u00ae vaccination","volume":"6","author":"Sei","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.virol.2024.110243_bib47","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S1474-4422(07)70267-3","article-title":"The neurotropic herpes viruses: herpes simplex and varicella-zoster","volume":"6","author":"Steiner","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.virol.2024.110243_bib48","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1348-0421.2000.tb02599.x","article-title":"IL-12, IFN-\u03b3, and TNF-\u03b1 released from mononuclear cells inhibit the spread of varicella-zoster virus at an early stage of varicella","volume":"44","author":"Torigo","year":"2000","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.virol.2024.110243_bib49","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1517\/14712598.2010.519332","article-title":"Production of adenovirus vectors and their use as a delivery system for influenza vaccines","volume":"10","author":"Vemula","year":"2010","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.virol.2024.110243_bib50","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.4161\/hv.26009","article-title":"Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of human immunodeficiency virus Type 1 (HIV-1)","volume":"9","author":"Wallace","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virol.2024.110243_bib51","first-page":"150","article-title":"Autoimmune\/inflammatory syndrome induced by adjuvants and thyroid autoimmunity","volume":"7","author":"Watad","year":"2016","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.virol.2024.110243_bib52","series-title":"Varicella-Zoster Virus","first-page":"341","article-title":"VZV T cell-mediated immunity","author":"Weinberg","year":"2010"},{"key":"10.1016\/j.virol.2024.110243_bib53","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus\u2013specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J. Infect. Dis."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224002642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682224002642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:31:32Z","timestamp":1764599492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682224002642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":53,"alternative-id":["S0042682224002642"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2024.110243","relation":{},"ISSN":["0042-6822"],"issn-type":[{"type":"print","value":"0042-6822"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric adenovirus-based herpes zoster vaccine with the tPA signal peptide elicits a robust T-cell immune response","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2024.110243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110243"}}